Navigation Links
Medical molecules designed to respond to visible light that can penetrate tissue

If you have ever covered a flashlight with your hand and seen the red light that still comes through, then you have seen light in the therapeutic window ?that magic wavelength that is not absorbed or reflected away by tissue. Scientists believe that they can use light at that wavelength to signal manmade molecules to release drugs at disease sites in the body.

Such possibilities will be discussed in a poster and a talk by Virginia Tech researchers presenting at the 229th American Chemical Society national meeting in San Diego on March 13-17.

Researchers in Karen Brewer's group at Virginia Tech have designed supramolecular complexes that can hold and, when signaled by light (photoinitiatied), will generate pharmaceutical compounds that can cleave DNA, such as in a tumor cell. "The challenge has been that tissue blocks light so we can't signal molecules deep within the body to deliver drug therapy," says Brewer, associate professor of chemistry.

Matthew Mongelli of Maywood N.J., a postdoctoral associate in chemistry, and his colleagues in chemistry and biology at Virginia Tech, have been working with Theralase Technologies Inc. to design molecular systems that use light that is in the therapeutic window. Starting with a complex with known DNA cleaving qualities, they changed the light absorber unit to one that responds to the red wavelength.

"Investigations into polyazine supermolecular complexes containing Ru and Os with Rh centers that possess photoactive MMCT states: Visible light induced, oxygen independent DNA photocleavage (INOR 329)," will be presented by Mongelli during the general poster session, 7 to 9 p.m., Sunday, March 13, in Convention Center Hall D. The poster has also been selected for the Sci_Mix session 7 to 9 p.m. Monday, March 14, in the Convention Center's Sails Pavilion.

Co-authors are Brewer; undergraduate chemistry students Matthew Jeletic of Centreville, Va. and Jerita Dubash of Ashburn, Va.; and Biology
'"/>

Source:Virginia Tech


Page: 1 2

Related biology news :

1. UCLA Study Shows One-Third of Drug Ads in Medical Journals Do Not Contain References Supporting Medical Claims
2. Medical whistleblowers speak out
3. Medical experts: US unlikely to have enough vaccines to stop avian flu
4. Inflammatory molecules released by pollen trigger allergies
5. DNA constraints control structure of attached macromolecules
6. Scientists discover that three molecules may be developed into new Alzheimers drugs
7. Physical and functional interaction of key cell growth molecules linked to cancer
8. Scientists discover new way to look at how molecules twist and turn on water
9. Scientists learn to predict protein-stabilizing ability of small molecules
10. Tiny RNA molecules fine-tune the brains synapses
11. Convergent evolution of molecules in electric fish
Post Your Comments:
(Date:7/24/2014)... Scientists at The New York Stem Cell Foundation ... creating a viable cell replacement therapy for multiple ... For the first time, NYSCF scientists generated induced ... of patients with primary progressive multiple sclerosis and ... these stem cells into becoming oligodendrocytes, the myelin-forming ...
(Date:7/24/2014)... examples of how wildlife loss leads to conflict among ... Wildlife Conservation Society (WCS) Health & Ecosystems: Analysis ... for an interdisciplinary approach to tackle global biodiversity decline. ... 15% of the world,s people and provides protein for ... should come as no surprise that today,s unprecedented loss ...
(Date:7/24/2014)... - July 24, 2014 -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) ... long-term, randomized, active control Phase 3 study of Zerenex ... binder, for the treatment of hyperphosphatemia in patients with ... (PhosphatE binding and iRon delivery with FErric CiTrate in ... of the American Society of Nephrology ( JASN ...
Breaking Biology News(10 mins):NYSCF scientists one step closer to cell therapy for multiple sclerosis patients 2New study draws links between wildlife loss and social conflicts 2Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 2Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 3Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 4
... identified several proteins in mice that might act as ... first step to finding a more reliable way to ... and teenagers use illegally to boost muscle and reduce ... in San Francisco today, scientists John Kopchick and Juan ...
... For those patients who receive the nearly 40 ... deficiency, a new oral option may soon exist. ... B12 deficiency can lead to a wide spectrum of ... Vitamin B12 deficiency is a significant health issue. Nearly ...
... ADHD-associated version of the human gene DRD4 is linked ... malnourishment in their settled cousins, according to new research ... University of Wisconsin-Milwaukee (UWM). A study by UWM ... Boston University and UNLV shows that a particular version ...
Cached Biology News:Scientists find potential protein biomarkers for growth hormone 2New technology may prevent vitamin B12 deficient seniors and vegetarians from needing injections 2Did the gene for ADHD help our nomadic ancestors? 2
(Date:7/24/2014)... York, NY - July 24, 2014 -- Keryx Biopharmaceuticals, ... from the long-term, randomized, active control Phase 3 study ... iron-based phosphate binder, for the treatment of hyperphosphatemia in ... PERFECTED study (PhosphatE binding and iRon delivery with FErric ... Journal of the American Society of Nephrology ...
(Date:7/24/2014)... 24, 2014 -- A novel combination of microscopy and ... Energy,s Oak Ridge National Laboratory an unprecedented look at ... physical and electrochemical properties. , The research team ... the surface of a perovskite manganite, a complex material ... avenue to understand surface behavior could benefit researchers who ...
(Date:7/24/2014)... 24, 2014 Gain recognition for ... Chain of the biotech industry. Nominations are now ... brought to you by the Bio Supply ... supply chain management professionals for the past 7 ... of the Biotech industry – Manufacturers, Service Providers, ...
(Date:7/24/2014)... , July 24, 2014  Now available is ... home. Rehealth Regenerative Therapies , located in ... other physically active people a new health option: ... Regardless of age, countless patients suffer from joint and ... such as muscle tears, torn rotator cuff, tennis elbow, ...
Breaking Biology Technology:Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 2Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 3Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 4ORNL study reveals new characteristics of complex oxide surfaces 2Call for Submission: BSMA’s Supply Chain Management Innovation Awards 2Call for Submission: BSMA’s Supply Chain Management Innovation Awards 3Stem Cells In Sports Injuries, Joints And Muscular Pain 2Stem Cells In Sports Injuries, Joints And Muscular Pain 3
... (NYSE: SGP ) today announced that the ... review status to the company,s,New Drug Application (NDA) ... reverse the effects of certain,muscle relaxants, marketed in ... bromide. Muscle relaxants are used as part of,general ...
... The following statement was issued,today by the law firm of ... given that a class action lawsuit was filed in the,United ... on,behalf of all purchasers of the securities of Sanofi-Aventis (NYSE: ... through June 13, 2007,inclusive (the "Class Period")., If you ...
... Dec. 31 Pharmasset, Inc.,(Nasdaq: VRUS ), ... and commercializing novel drugs to treat viral,infections, reported ... 30, 2007. Pharmasset reported a net loss attributable ... share, as compared to a net loss,attributable to ...
Cached Biology Technology:Schering-Plough Announces New Drug Application for Sugammadex Assigned Priority Review Status by U.S. FDA 2Schering-Plough Announces New Drug Application for Sugammadex Assigned Priority Review Status by U.S. FDA 3Schering-Plough Announces New Drug Application for Sugammadex Assigned Priority Review Status by U.S. FDA 4Shareholder Class Action Filed Against Sanofi-Aventis by the Law Firm of Schiffrin Barroway Topaz & Kessler, LLP 2Shareholder Class Action Filed Against Sanofi-Aventis by the Law Firm of Schiffrin Barroway Topaz & Kessler, LLP 3Pharmasset Reports Fiscal Year End 2007 Financial Results 2Pharmasset Reports Fiscal Year End 2007 Financial Results 3Pharmasset Reports Fiscal Year End 2007 Financial Results 4Pharmasset Reports Fiscal Year End 2007 Financial Results 5Pharmasset Reports Fiscal Year End 2007 Financial Results 6Pharmasset Reports Fiscal Year End 2007 Financial Results 7Pharmasset Reports Fiscal Year End 2007 Financial Results 8Pharmasset Reports Fiscal Year End 2007 Financial Results 9
... designed for two-dimensional electrophoresis (2D) and ... in this marker have been selected ... a 2D gel. The pI range ... Mol wt: 17,000-89,000 Physical Form: ...
... to test the crossreactivity of an antibody ... commonly used as blocking reagents or antigen ... different protein preparations on a nitrocellulose membrane. ... specificity, QC of purified antibodies, selection of ...
... is based on PI's experience in high-resolution ... a decade. PI Hexapods were originally used ... adjustments over wide ranges in small step ... freedom with 3 m minimum incremental motion ...
... can provide custom microplate coating using advanced automated high throughput ... plate formats. We can also accommodate virtually any lot size ... L):, , 8 and ... microplate, 384 well microplate, ...
Biology Products: